Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11078032 | 0.87 | GABRA1 (0.50) | LMNAOPRK1PDE4D | |
| SCHEMBL11651359 | 0.84 | CHRM1 (0.47) | CHRM1LMNADRD3OPRK1CYP3A4 | |
| SCHEMBL11086081 | 0.83 | OPRK1 (0.50) | CHRM1LMNAOPRK1PDE4DKCNH2 | |
| SCHEMBL30320290 | 0.82 | LMNA (0.57) | CHRM1LMNADRD3OPRK1CYP3A4 | |
| SCHEMBL7380121 | 0.82 | LMNA (0.57) | CHRM1LMNADRD3OPRK1CYP3A4 | |
| SCHEMBL7311280 | 0.81 | CHRM1 (0.51) | CHRM1LMNADRD3OPRK1CYP3A4 | |
| SCHEMBL11610206 | 0.79 | CHRM1 (0.51) | CHRM1LMNADRD3OPRK1CYP3A4 | |
| SCHEMBL28551700 | 0.79 | CHRM1 (0.51) | CHRM1LMNADRD3OPRK1CYP3A4 | |
| SCHEMBL7307548 | 0.78 | LMNA (0.50) | CHRM1LMNADRD3OPRK1CYP3A4 | |
| SCHEMBL11826517 | 0.77 | CHRM1 (0.47) | CHRM1LMNADRD3OPRK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4299126-A2 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3160969-B1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11136322-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210163490-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2021-06-03 | — | — | US | disclosed |
| US-10844070-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200181155-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2020-06-11 | — | — | US | disclosed |
| US-20200062759-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| US-10266534-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170197967-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2017-07-13 | — | — | US | disclosed |
| EP-3160969-A2 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200766-A2 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-0801651-B1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | disclosed |
| US-6174881-B1 | USED AS ANXIOLYTIC AND/OR ANTICONVULSANT AND/OR MUSCLE RELAXANT AGENTS; SEDATIVES OR HYPNOSIS; WATER-SOLUBLE AMINE SALTS; FAST-ACTING | HOFFMAN-LA ROCHE INC. | 2001-01-16 | — | — | US | disclosed |
| EP-0801651-A1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-22 | — | — | EP | disclosed |
| WO-1996020941-A1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-07-11 | — | — | WO | disclosed |
| US-4178378-A | ANTIEPILEPTIC AGENT, TRANQUILIZER, AND ANTICONVULSANT | CIBA-GEIGY CORPORATION (US) | 1979-12-11 | — | — | US | disclosed |
| US-3946032-A | Acetal derivatives of 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde | CIBA-GEIGY CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844070-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | SLC6A13, SI, SLC6A11 | CHRM1 746/4885LMNA 4775/4885DRD3 1168/4885 |
| US-11136322-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | SLC6A13, SI, SLC6A11 | CHRM1 746/4885LMNA 4775/4885DRD3 1168/4885 |
| US-20200181155-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | SLC6A13, SI, SLC6A11 | CHRM1 746/4885LMNA 4775/4885DRD3 1168/4885 |
| US-20200062759-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | SLC6A13, SI, SLC6A11 | CHRM1 746/4885LMNA 4775/4885DRD3 1168/4885 |
| US-10266534-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | SLC6A13, SI, SLC6A11 | CHRM1 746/4885LMNA 4775/4885DRD3 1168/4885 |
| US-20210163490-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | SLC6A13, SI, SLC6A11 | CHRM1 746/4885LMNA 4775/4885DRD3 1168/4885 |
| US-20170197967-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | SLC6A13, SI, SLC6A11 | CHRM1 746/4885LMNA 4775/4885DRD3 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.